Introduction: It has been posited that elevated AMH due to follicular excess, rather than facilitating ovulation, plays a critical role in the arrest of follicular growth that is characteristic of PCOS. Since 2003, the diagnostic criteria for PCOS particularly TVS which have problem with acceptance included an assessment of the follicular pool by specific ultrasound findings. There is support for the notion that AMH serves as a surrogate marker for the antral follicle count in the diagnosis of PCOS.

Aims: Anti-mullerian hormone level in the polycystic ovarian syndrome and it association with clinical parameters.

Material and Method: observational Cross-sectional study carried out in the department of Endocrinology and metabolism, Medical College, Kolkata from march 2017 to January 2019.Total number of study subjects were 207 out of which 138 were cases.

Results: The mean AMH were significantly higher in the case as compare to control group with a value of 11.15±4.6 ng/ml and 3.68±2.09 ng/ml respectively. The Spearman s rank (rho) correlation of Anti – mullerian Hormone with ovarian morphology and AMH is strongly and significantly associated with ovarian volume (r = 0.506, p<0.00) and follicular number ( r= 0.0582, p <0.001 ) case group. ROC curve of the AMH: ROC curve was drawn to determined the cut-off of AMH in our PCOS population showed the cut-off AMH > 5.06 ng/ml with the sensitivity & specificity of 97.8% and 80.4% respectively.

Keywords: Anti Mullerian hormone , ovarian volume , follicular size , follicle count.

1. Asunción, R. M. Calvo, J. L. San Millan, J. Sancho, S. Avila and H. F. Escobar-Morreale, “A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain,” The Journal of Clinical Endocrinology and Metabolism, Vol.85, No. 7, 2000, pp. 2434-2438.
2. Azziz, K. S. Woods, R. Reyna, T. J. Key, E. S. Kno-chenhauer and B. O. Vildiz, “The Prevalence and Features of the Polycystic Ovary Syndrome in Unselected Population,” The Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 6, 2004, pp. 2745-2749.
3. Diamanti-Kandarakis, C. R. Kouli, A. T. Bergiele, F. A. Filandra, T. C. Tsianateli, G. G. Spina, E. D. Zapanti and M. I. Bartzis, “A Survey of the Polycystic Ovary Syndrome in the Greek Island of Lesbos: Hormonal and Metabolic Profile,” The Journal of Clinical Endocrinology and Metabolism, Vol. 84, No. 11, 1999, pp. 4006- 4011.
4. Alberti KG, Zimmet P, Shaw J: Metabolic definition. A Consensus Statement from the International Diabetes Federation. Diabetic Med 2006; 23:46.
5. Cussons AJ, Stuckey BGA, Watts GF: Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006; 185: 227.
6. Serder E Bulun, Physiology and pathology and pathology of female reproductive axis. Williams textbook of Endocrinology 12^th Revised 2003. consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and sterility.2004;81:19–25.
7. Casadei L, Madrigale A, Puca F, Manicuti C, Emidi E, Piccione E, Dewailly D. The role of serum anti-Mullerian hormone (AMH) inthe hormonal diagnosis of polycystic ovary syndrome.Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013;29:545–550.
8. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, Duhamel A, Catteau-Jonard S. Diagnosis of polycystic ovary syndrome(PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26:3123–3129.
9. Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of then polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism. 2006;91:941–945.
10. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ Escobar-Morreale HF. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Human reproduction update. 2014;20:334–352
11. Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic descriptionbe replaced? Hum Reprod. 2012;27:2494– 2502.
12. Homburg R, Ray A, Bhide P, Gudi A, Shah A, Timms P, Grayson K. The relationship of serum anti-Mullerian hormone with polycysticovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013;28:1077–1083.
13. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, Cohen A,
14. Hougaard DM, Nyboe Andersen A. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti – Mullerian hormone. Hum Reprod. 2014;29:791–801.
15. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Human reproduction update. 2004;10:107–117.
16. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. The Journal of clinical endocrinology and metabolism. 2003;88:5957–5962.
17. Grossman MP, Nakajima ST, Fallat ME, Siow Y. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertility and sterility. 2008;89: 1364–1370.
18. Pellatt L, Rice S, Dilaver N, Heshri A, Galea R, Brincat M, Brown K, Simpson ER, Mason HD. Anti-Mullerian hormone reduces folliclesensitivity to follicle-stimulating hormone in human granulose cells. Fertility and sterility. 2011;96:1246–1251 e1241.
19. Vigier B, Forest MG, Eychenne B, Bezard J, Garrigou O, Robel P, Josso N. Anti-Mullerian hormone produces endocrine sex reversalof fetal ovaries. Proceedings of the National Academy of Sciences of the United States of America. 1989;86:3684–3688.n
20. Nelson VL, Legro RS, Strauss JF, 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Molec Endocrinol. 1999;13:946–957.
21. Hart R. Definitions, prevalence and symptoms of polycystic ovaries and the polycysticovary syndrome. In: Allahbadia GN, Agrawal R, editors. Polycystic Ovary Syndrome. Kent, UK:Anshan, Ltd; 2007. pp. 15–26.
22. Khoury MY, Baracat EC, Pardin DP, Haidar MA, da Motta EL, de Lima GR. Polycystic ovary syndrome: Clinical and laboratory evaluation. Sao Paulo Med J 1996; 114: 1222-1225.
23. Arefi S. PCO prevalence and association with menstrual irregularity in adolescence. J Reprod Infertil 2000; 5: 57-62.
24. Prevalence and symptomatology of polycystic ovarian syndrome in Indian women: is there a rising incidence? Anjali Choudhary*, Shweta Jain, Priyanka Chaudhari International Journal of Reproduction, Contraception, Obstetrics and Gynecology Choudhary A et al. Int J Reprod Contracept Obstet Gynecol. 2017 Nov;6(11):4971-4975
25. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev. 2000;21(4):347–362
26. Lobo RA. Hirsutism in Polycystic ovary syndrom current concepts. Clin Obtset Gynecol 199; 34: 817-826.
27. Cibula D, Hill M, Vohradnikova O, Kuzel D, Fanta M, Zivny J. The role of androgens indetermining acne severity in adult women. Br J Dermatol 2000; 143: 399-404.
28. Bunker CB, Newton JA, Kilborn J, Patel A, Conway GS, Jacobs HS, et al. Most women withacne have polycystic ovaries. Br J Dermatol 1989; 121: 675-680.
29. Dolfing J, van Haard P, Schweitzer D, Wolffenbuttel B. Metabolic and hormonal parameters in lean PCOS women. Endocrine Abstracts 29,
30. Fallat ME, Siow Y, Marra M, Cook C, Carrillo A. Mullerian ‑i nhibiting substance infollicular fluid and serum: A comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. mFertil Steril 1997;67:962‑5.
31. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti -Mullerian hormone. Reproduction 2002;124:601-609.
32. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti -Mullerian hormone. Reproduction 2002;124:601-609.
33. A comparison of current acne grading systems and proposal of novel system. Doshi A, Zaheer A, Stiller MJ.PMID: 9248884 DOI: 10.1046/j.1365-4362.1997.00099.x. Int J Dermatol. 1997 Jun;36(6):416-8.

Dr Anirban Sinha

Assistant Professor, Department of Endocrinology and Metabolism